Abstract
During Phase I of this study 39 males, 20-43 years of age with a history of previous polio immunization, were screened for antibody to poliovirus. 49% (19/39) had no detectable neutralizing antibody to at least 1 of the 3 poliovirus types at ≥ 1:8 and 31% (12/39) were negative at ≥ 1;4. 12 subjects seropositive at ≥ 1;4 received either 0.25, 0.5 or 1.0 ml of a highly potent inactivated poliovaccine manufactured from Sabin-strain attenuated poliovirus with D antigen content of 40:25:70 units/ml for types 1, 2 and 3 poliovirus respectively. Approximately 6 months later, 9 subjects previously identified as seronegative to at least 1 type of poliovirus despite a history of adequate polio vaccination, entered Phase II of this study. These subjects received 0.5 ml of the Sabin-strain IPV and had antibody determinations at 2, 4, 7 and 30 days post vaccination. In the first trial this vaccine was safe and highly immunogenic (see Table). All seronegative Phase II subjects also responded to the vaccine. The immune status of these individuals with waning antibody continues to be of concern, particularly in view of the recent outbreak of polio in Finland.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murph, J., Grose, C., Cuthbertson, G. et al. FIRST CLINICAL TRIAL WITH SABIN INACTIVATED POLIO VACCINE. Pediatr Res 21 (Suppl 4), 330 (1987). https://doi.org/10.1203/00006450-198704010-00980
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-00980